KEYTRUDA + Chemo Showed Sustained OS Benefit vs Chemo Alone in in KEYNOTE-189 and KEYNOTE-407 trials for mNSCLC
“The overall survival findings from KEYNOTE-189 and KEYNOTE-407 changed the way patients with metastatic non-small cell lung cancer were treated and established KEYTRUDA plus chemotherapy as a foundational first-line treatment for this devastating disease,” said Dr. Eliav Barr, senior vice president, head of global clinical development and chief medical officer, Merck Research Laboratories. “Now, with more than five years of follow-up, these studies continue to show impressive survival outcomes and durable responses for patients receiving KEYTRUDA in combination with chemotherapy. In fact, in both studies, of the approximately 55 patients who completed two years of treatment, about 70% were alive at five years.”
Share:
More News
“The initial efficacy data from the Part C studies are consistent with the encouraging efficacy signals we previously reported for Parts A and B of THIO-101, including an 88% disease control rate in third-line NSCLC patients. This measure of efficacy is close to triple the reported outcome for standard-of-care chemotherapy
“Patients with non-muscle invasive bladder cancer continue to face a significant risk of disease recurrence despite available treatment options,” said Mark Schoenberg, M.D., Chief Medical Officer of UroGen. “UGN-501 is an investigational next-generation oncolytic virus designed to selectively destroy tumor cells while generating an anti-tumor immune response. FDA clearance of
“Whitehawk has established strong expertise in ADC technology and oncology drug development,” said Dr. Yuelei Shen, President and CEO of Biocytogen. “This collaboration further expands the application of Biocytogen’s fully human bispecific antibodies in ADC development. We look forward to supporting the efficient advancement of multiple programs by contributing high-quality
Hesham Abdullah, Senior Vice President, Global Head Oncology, R&D, GSK, said: “The AZUR-1 results support the potential for dostarlimab to transform treatment for dMMR/MSI-H locally advanced rectal cancer. For many patients today, rectal cancer treatment comes with the tolerability burden and lasting impacts from chemotherapy, radiation and surgery. These data